In a regulatory filing, Vertex Pharmaceuticals CMO Carmen Bozic disclosed the sale of 2,280 common shares of the company on July 10 at a price of $487.34 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $455 from $402 at Morgan Stanley
- Vertex Pharmaceuticals announces FDA acceptance of triple combination therapy
- Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
- Vertex Pharmaceuticals initiated with a Buy at Redburn Atlantic